ReShape Lifesciences Inc. (33)

Browse by Contract Category

Contracts

Fourth Amendment to Credit Agreement, dated January 19, 2021, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on January 20, 2021)
Form of Voting and Support Agreement by and among ReShape Lifesciences Inc. and certain stockholders of Obalon Therapeutics, Inc (Filed With SEC on January 20, 2021)
Agreement and Plan of Merger, dated as of January 19, 2021, by and among Obalon Therapeutics, Inc., Optimus Merger Sub, Inc., and ReShape Lifesciences Inc (Filed With SEC on January 20, 2021)
Description of Registrants Securities (Filed With SEC on April 30, 2020)
ReShape Lifesciences Inc. Change in Control Plan, dated as of February 28, 2020 (Filed With SEC on March 5, 2020)
Credit Facility Agreement, dated as of January 19, 2021, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on January 20, 2021)
Third Amendment to Credit Agreement, dated December 16, 2020, by and between the Company and Armistice Capital Master Fund Ltd (Filed With SEC on December 22, 2020)
Series G Common Stock Purchase Warrant, dated September 14, 2020, issued by the Company to Armistice Capital Master Fund Ltd (Filed With SEC on September 15, 2020)
Second Amendment to Credit Agreement, dated September 14, 2020, by and between the Company and Armistice Capital Master Fund Ltd (Filed With SEC on September 15, 2020)
Series G Common Stock Purchase Warrant, dated March 25, 2020, issued by the Company to Armistice Capital Master Fund Ltd (Filed With SEC on April 30, 2020)
Registration Rights Agreement, dated March 25, 2020, by and between the Company and Armistice Capital Master Fund Ltd (Filed With SEC on April 30, 2020)
Guarantee and Collateral Agreement, dated March 25, 2020, by and between the Company, ReShape Medical LLC and Armistice Capital Master Fund Ltd (Filed With SEC on April 30, 2020)
Credit Agreement, dated March 25, 2020, by and between the Company and Armistice Capital Master Fund Ltd (Filed With SEC on April 30, 2020)
Amendment to Credit Agreement, dated March 31, 2020 by and between the Company and Armistice Capital Master Fund Ltd (Filed With SEC on March 31, 2020)
Guarantee and Collateral Agreement, dated March 25, 2020, by and between the Company, ReShape Medical LLC and Armistice Capital Master Fund Ltd (Filed With SEC on March 31, 2020)
Credit Agreement, dated March 25, 2020, by and between the Company and Armistice Capital Master Fund Ltd., as amended (Filed With SEC on March 31, 2020)
Amendment to Series G Common Stock Purchase Warrant, dated March 25, 2020 issued by the Company to Armistice Capital Master Fund Ltd., as amended (Filed With SEC on March 31, 2020)
Registration Rights Agreement, dated March 25, 2020, by and between the Company and Armistice Capital Master Fund Ltd (Filed With SEC on March 31, 2020)
Series G Common Stock Purchase Warrant, dated March 25, 2020, issued by the Company to Armistice Capital Master Fund Ltd., as amended (Filed With SEC on March 31, 2020)
Form of Amended and Restated Registration Rights Agreement (Filed With SEC on September 30, 2019)
Form of Series F Warrant (Filed With SEC on September 30, 2019)
Form of Series E Warrant (Filed With SEC on September 30, 2019)
Form of Securities Purchase Agreement (Filed With SEC on September 30, 2019)
Form of Registration Rights Agreement (Filed With SEC on June 19, 2019)
Form of Series C Prefunded Warrant (Filed With SEC on June 19, 2019)
Form of Series B Warrant (Filed With SEC on June 19, 2019)
Form of Series A Warrant (Filed With SEC on June 19, 2019)
Form of Securities Purchase Agreement (Filed With SEC on June 19, 2019)
Retention bonus agreement, dated April 12, 2019 by and between ReShape Lifesciences Inc and Scott P. Youngstrom (Filed With SEC on April 17, 2019)
Form of Debenture (Filed With SEC on April 3, 2019)
Form of Registration Rights Agreement (Filed With SEC on April 3, 2019)
Form of Security Agreement (Filed With SEC on April 3, 2019)
Form of Securities Purchase Agreement (Filed With SEC on April 3, 2019)